Compare Stocks: VCYT, TWST, EXEL, and ASND

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASND Ascendis Pharma A/S	$228.03 +0.1%	$248.52	$186.05 ▼ $282.15	$14.21B	0.38	871,766 shs	783,210 shs
EXEL Exelixis	$58.85 +0.8%	$55.97	$33.76 ▼ $61.14	$14.47B	0.47	2.04 million shs	2.58 million shs
TWST Twist Bioscience	$205.00 +8.7%	$138.77	$23.30 ▼ $207.90	$11.83B	2.19	2.26 million shs	3.20 million shs
VCYT Veracyte	$47.67 +4.1%	$44.50	$29.45 ▼ $60.91	$3.68B	1.95	1.44 million shs	1.29 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASND Ascendis Pharma A/S	0.00%	+1.01%	-15.78%	-14.95%	+11.67%
EXEL Exelixis	0.00%	+0.40%	-1.05%	+5.15%	+45.65%
TWST Twist Bioscience	0.00%	+3.19%	+51.27%	+88.80%	+507.24%
VCYT Veracyte	0.00%	+0.84%	+7.71%	-21.00%	+27.25%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASND Ascendis Pharma A/S	$228.03 +0.1%	$248.52	$186.05 ▼ $282.15	$14.21B	0.38	871,766 shs	783,210 shs
EXEL Exelixis	$58.85 +0.8%	$55.97	$33.76 ▼ $61.14	$14.47B	0.47	2.04 million shs	2.58 million shs
TWST Twist Bioscience	$205.00 +8.7%	$138.77	$23.30 ▼ $207.90	$11.83B	2.19	2.26 million shs	3.20 million shs
VCYT Veracyte	$47.67 +4.1%	$44.50	$29.45 ▼ $60.91	$3.68B	1.95	1.44 million shs	1.29 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASND Ascendis Pharma A/S	0.00%	+1.01%	-15.78%	-14.95%	+11.67%
EXEL Exelixis	0.00%	+0.40%	-1.05%	+5.15%	+45.65%
TWST Twist Bioscience	0.00%	+3.19%	+51.27%	+88.80%	+507.24%
VCYT Veracyte	0.00%	+0.84%	+7.71%	-21.00%	+27.25%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASND Ascendis Pharma A/S	3.00	Buy	$310.75	36.28% Upside
EXEL Exelixis	2.35	Hold	$50.29	-14.55% Downside
TWST Twist Bioscience	2.50	Moderate Buy	$115.27	-43.77% Downside
VCYT Veracyte	2.82	Moderate Buy	$55.78	17.01% Upside

Current Analyst Ratings Breakdown

Latest VCYT, TWST, EXEL, and ASND Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/1/2026	TWST Twist Bioscience	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$107.00 ➝ $212.00
9/29/2026	TWST Twist Bioscience	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$160.00 ➝ $190.00
9/25/2026	ASND Ascendis Pharma A/S	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$300.00
9/24/2026	VCYT Veracyte	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C+) ➝ Hold (C)
9/21/2026	TWST Twist Bioscience	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/18/2026	TWST Twist Bioscience	BWS Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell	$45.00
9/17/2026	TWST Twist Bioscience	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$120.00 ➝ $160.00
9/16/2026	ASND Ascendis Pharma A/S	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$344.00
9/15/2026	VCYT Veracyte	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/15/2026	ASND Ascendis Pharma A/S	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Outperform	$287.00
9/14/2026	EXEL Exelixis	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform

(Data available from 10/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASND Ascendis Pharma A/S	$814.57M	17.46	N/A	N/A	($2.97) per share	-76.78
EXEL Exelixis	$2.32B	6.28	$3.05 per share	19.29	$8.06 per share	7.30
TWST Twist Bioscience	$376.57M	34.14	N/A	N/A	$7.84 per share	26.15
VCYT Veracyte	$517.15M	7.41	$1.55 per share	30.75	$16.57 per share	2.88

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASND Ascendis Pharma A/S	-$258M	$12.89	17.69	25.54	N/A	70.99%	32.54%	7.71%	11/11/2026 (Estimated)
EXEL Exelixis	$782.57M	$3.18	18.51	15.82	1.74	35.33%	42.17%	31.76%	11/3/2026 (Estimated)
TWST Twist Bioscience	-$77.67M	-$2.22	N/A	N/A	N/A	-31.66%	-28.64%	-19.94%	11/13/2026 (Estimated)
VCYT Veracyte	$66.35M	$1.41	33.81	30.95	N/A	20.37%	9.26%	8.61%	11/3/2026 (Estimated)

Latest VCYT, TWST, EXEL, and ASND Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	ASND Ascendis Pharma A/S	$1.71	$1.0270	-$0.6830	$3.23	$376.75 million	$387.22 million
8/5/2026	Q2 2026	EXEL Exelixis	$0.8530	$0.91	+$0.0570	$0.8438	$636.40 million	$628.69 million
8/3/2026	Q3 2026	TWST Twist Bioscience	-$0.5063	-$0.56	-$0.0538	-$0.56	$114.55 million	$118.38 million
7/30/2026	Q2 2026	VCYT Veracyte	$0.4103	$0.54	+$0.1297	$0.31	$144.59 million	$150.32 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASND Ascendis Pharma A/S	N/A	N/A	N/A	N/A	N/A
EXEL Exelixis	N/A	N/A	N/A	N/A	N/A
TWST Twist Bioscience	N/A	N/A	N/A	N/A	N/A
VCYT Veracyte	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASND Ascendis Pharma A/S	0.27	2.99	2.32
EXEL Exelixis	N/A	3.46	3.38
TWST Twist Bioscience	0.03	2.67	2.38
VCYT Veracyte	N/A	9.16	8.80

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ASND Ascendis Pharma A/S	N/A
EXEL Exelixis	85.27%
TWST Twist Bioscience	N/A
VCYT Veracyte	N/A

Insider Ownership

Company	Insider Ownership
ASND Ascendis Pharma A/S	40.00%
EXEL Exelixis	2.60%
TWST Twist Bioscience	3.08%
VCYT Veracyte	1.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ASND Ascendis Pharma A/S	1,189	62.38 million	37.43 million	Optionable
EXEL Exelixis	1,077	247.78 million	241.34 million	Optionable
TWST Twist Bioscience	979	62.71 million	60.78 million	Optionable
VCYT Veracyte	755	80.39 million	79.11 million	Optionable

VCYT, TWST, EXEL, and ASND Headlines

Recent News About These Companies

Veracyte (VCYT) Is Down 9.0% After New Level 1B1 Decipher Prostate Data at ASTRO 2026

October 2 at 2:35 PM | finance.yahoo.com

Veracyte (VCYT) Could Be 22% Undervalued After New Decipher Phase III Data

October 2 at 2:35 PM | finance.yahoo.com

Could Veracyte (VCYT) Change Prostate Cancer Care With New Phase III Data?

October 1, 2026 | finance.yahoo.com

Veracyte, Inc. Reports NRG/RTOG 0815 Analysis Shows Decipher Prostate Genomic Classifier Predicts Benefit From Adding Short-Term Androgen Deprivation Therapy To Dose-Escalated ...

September 29, 2026 | marketscreener.comM

Veracyte's Decipher Test Predicts Hormone Therapy Benefit In Phase 3 Prostate Cancer Analysis

September 29, 2026 | rttnews.com

Phase III Trial Demonstrates Veracyte’s Decipher Prostate Test Predicts Benefit from Adding Hormone Therapy to Radiation

September 29, 2026 | markets.businessinsider.com

Phase III Trial Demonstrates Veracyte's Decipher Prostate Test Predicts Benefit from Adding Hormone Therapy to Radiation

September 29, 2026 | globenewswire.com

Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026

September 25, 2026 | globenewswire.com

Veracyte (NASDAQ:VCYT) Stock Falls 5.7% - Time to Sell?

September 25, 2026 | marketbeat.com

Veracyte (VCYT) Surges 10.8%: Is This an Indication of Further Gains?

September 25, 2026 | zacks.com

Veracyte (NASDAQ:VCYT) Shares Up 6.5% - Still a Buy?

September 24, 2026 | marketbeat.com

John Leite Sells 4,015 Shares of Veracyte (NASDAQ:VCYT) Stock

September 22, 2026 | marketbeat.com

Veracyte Acquires Convergent Genomics For Up To $180 Million To Add Urinary Tumor DNA Bladder Cancer Platform

September 21, 2026 | pulse2.comP

Bank of America Corp DE Invests $64.74 Million in Veracyte, Inc. $VCYT

September 20, 2026 | marketbeat.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Veracyte (VCYT), IQVIA Holdings (IQV) and Chemed (CHE)

September 19, 2026 | theglobeandmail.com

Squarepoint Ops LLC Sells 49,301 Shares of Veracyte, Inc. $VCYT

September 19, 2026 | marketbeat.com

Corient Private Wealth LP Has $9.52 Million Holdings in Veracyte, Inc. $VCYT

September 17, 2026 | marketbeat.com

Veracyte (NASDAQ:VCYT) Director Jens Holstein Sells 5,000 Shares

September 16, 2026 | marketbeat.com

Veracyte, Inc. (NASDAQ:VCYT) Receives Consensus Recommendation of "Moderate Buy" from Analysts

September 16, 2026 | marketbeat.com

Veracyte Adds Another Stream to Bladder Franchise, UBS Says

September 15, 2026 | marketscreener.comM

Veracyte, Inc. (VCYT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 15, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VCYT, TWST, EXEL, and ASND Company Descriptions

Ascendis Pharma A/S NASDAQ:ASND

$228.03 +0.16 (+0.07%)

Closing price 04:00 PM Eastern

Extended Trading

$228.07 +0.04 (+0.02%)

As of 07:30 PM Eastern

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Exelixis NASDAQ:EXEL

$58.85 +0.46 (+0.79%)

Closing price 04:00 PM Eastern

Extended Trading

$58.84 -0.01 (-0.02%)

As of 07:30 PM Eastern

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Twist Bioscience NASDAQ:TWST

$205.00 +16.33 (+8.66%)

Closing price 04:00 PM Eastern

Extended Trading

$206.50 +1.50 (+0.73%)

As of 07:59 PM Eastern

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Veracyte NASDAQ:VCYT

$47.67 +1.86 (+4.06%)

Closing price 04:00 PM Eastern

Extended Trading

$47.78 +0.10 (+0.22%)

As of 07:47 PM Eastern

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VCYT, TWST, EXEL, and ASND Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VCYT, TWST, EXEL, and ASND Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VCYT, TWST, EXEL, and ASND Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VCYT, TWST, EXEL, and ASND Company Descriptions

Ascendis Pharma A/S NASDAQ:ASND

Exelixis NASDAQ:EXEL

Twist Bioscience NASDAQ:TWST

Veracyte NASDAQ:VCYT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VCYT, TWST, EXEL, and ASND Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VCYT, TWST, EXEL, and ASND Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VCYT, TWST, EXEL, and ASND Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VCYT, TWST, EXEL, and ASND Company Descriptions

Ascendis Pharma A/S NASDAQ:ASND

Exelixis NASDAQ:EXEL

Twist Bioscience NASDAQ:TWST

Veracyte NASDAQ:VCYT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools